Search Results
146 results
Your search is now limited to «Non-Hodgkin Lymphoma» expert search.
GlobeNewswire 01/22/2019 07:30
About Marginal Zone Lymphoma Marginal zone lymphoma (MZL) comprises a group of indolent (slow growing) B-cell non-Hodgkin lymphomas (NHLs) that begin forming in the marginal zone of lymphoid tissue.
More from GlobeNewswire:
BioNewsFeeds 01/21/2019 13:49
Groups 3 and 4 will include NHL patients (particularly those with Waldenstrom’s macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma), who failed a prior BTK inhibitor, and have (group 3) or don’t have (group 4) the C481 mutation.
More from BioNewsFeeds:
ClinicalTrials.gov 01/18/2019 12:00
Conditions : Metastatic Solid Tumors; Hodgkin Lymphoma; Non Hodgkin Lymphoma (NHL); Non-small Cell Lung Cancer (NSCLC); Melanoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Gastric Adenocarcinoma; Renal Cell Carcinoma (RCC); Urothelial Carcinoma; Esophageal Adenocarcinoma Intervention : Drug: INBRX-105 Sponsor : Inhibrx, Inc. Not yet recruiting.
More from ClinicalTrials.gov:
Lancet 01/18/2019 02:00
Peripheral T-cell lymphoma is a rare and heterogeneous subgroup of non-Hodgkin lymphoma, comprising approximately 10–15% of all cases.1 Although there is no consensus on the optimal front-line therapy, cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) has been widely adopted as the default reference regimen, with autologous stem cell transplantation consolidation performed in eligible patients.
Healio News 01/16/2019 09:18
The trials have included patients with mantle cell lymphoma, Waldenström’s macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma.
More from Healio News:
Benzinga 01/14/2019 16:15
In the United States, about 70,800 new cases of NHL were expected in 2014, with MCL representing about six percent (about 4,200 cases) of all new cases of NHL in the United Statesi.
More from Benzinga:
WN.com 01/11/2019 16:47
WASHINGTON - The first cancer patient to be treated as part of the CAR-T cell clinical trial at MedStar Georgetown University Hospital through Georgetown Lombardi Comprehensive Cancer Center is now in 'complete remission.' Daisy Diggs, 57, of Laurel, Md., volunteered for the experimental treatment after a lengthy battle with stage-three non-Hodgkin lymphoma, a type of blood cancer.
More from WN.com:
Business Wire 01/09/2019 08:00
There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma.
More from Business Wire:
Although a partnership between PatientsLikeMe and the Cutaneous Lymphoma Foundation (a patient-advocacy group) was made to help with patient recruitment, there was substantial overlap in participants across stages of the research study due to difficulty recruiting patients with these rare diseases.
Purpose:. p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including multiple myeloma (MM). On the basis of our promising findings in MM, we here characterize PAK4 expression and role in WM cells, as well effect of dual PAK4-NAMPT inhibitor (KPT-9274) against WM cell growth and viability. Experimental Design:. We have analyzed mRNA and protein expression levels of PAK4 in WM cells, and used loss-of-function approach to investigate its contribution to WM cell viability. We have further tested the in vitro and in vivo effect of KPT-9274 against WM cell growth and viability. Results:. We report here high-level expression and functional role of PAK4 in WM, as demonstrated by shRNA-mediat.
More from Clinical Cancer Research - Recent Issues (abstracts):
PubMed News (NIH) 12/30/2018 23:00
C. burnetii could be considered as a transcriptionnal risk factor for NHL, further investigations will be necessary to elucidated the cellular and molecular mechanisms involved in Cb-NHL association.
More from PubMed News (NIH):
PR Newswire 12/27/2018 15:00
HSINCHU, Taiwan and WUHAN, China, Dec. 27, 2018 /PRNewswire/ -- JHL Biotech announced today that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL).
More from PR Newswire:
PhysOrg.com 12/21/2018 08:38
This draft guidance comes after results of a phase 3 clinical trial showed that the drug was better than current treatment at stopping the lymphomas, called CD30-positive cutaneous T-cell lymphomas (CTCL), cancer getting worse.
More from PhysOrg.com:
Lympho Bob 12/17/2018 09:49
OncLive has an excellent video series on CAR-T. They usually spread their video series over a couple of weeks, with a new installment every few days. Today's installment is called " Expanding the Role of CAR T in Non-Hodgkin Lymphoma ," and it features comments from Dr. Nilanjan Ghosh of the Levin Cancer Institute in North Carolina; Dr. Leo Gordon from Northwestern Memorial Hospital in Chicago; and Dr. Matthew Lunning from the University of Nebraska Medical Center. This video is fourth in the series. The others cover some basic information about how CAR-T works, and some practical issues like cost. It's a good introduction to CAR-T. (And, of course, if you want to learn more, especially from a patient's perspective, you might consider check.
ecancer news 12/17/2018 06:01
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent therapy.
More from ecancer news:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications